Epidemiological data indicate an explosion of type 2 diabetes cases for women after menopause. What is responsible for that? The surprisingly protective role of estrogens, highlighted by the fact that a woman undergoing hormone replacement therapy has up to 35% less risks of developing type 2 diabetes than a woman without treatment. By elucidating how estrogen affects two of the hormones involved in glucose homeostasis, glucagon and GLP1, researchers at the University of Geneva (UNIGE), Switzerland, and at the Geneva University Hospitals (HUG) prove the value of estrogen supplementation from the onset of menopause. This research, published in JCI Insight, also shows that only one of the three estrogen receptors seems to be involved in this mechanism. This could ultimately provide much more targeted therapies with a specific molecule that would prevent patients the sometimes embarrassing side effects when treated with a too powerful hormonal therapy.
Diabetes experts know that pre-menopausal women are less likely than men to develop type 2 diabetes. However, after menopause, the trend reverses very clearly, highlighting the protective role of women sexual hormones and especially estrogens. But what is their specific effect on metabolism? This question was answered by the team led by Jacques Philippe, Diabetes specialist at UNIGE Faculty of Medicine and Head of the HUG Department of Endocrinology, Diabetes, Hypertension and Nutrition.
“A number of scientists are working on the effect of estrogens on pancreatic insulin-producing cells,” says Sandra Handgraaf, a researcher at the Faculty of Medicine and the first author of this work. “But its effect on glucagon-producing cells, another hormone regulating blood sugar, had never been explored before. Indeed, if the pancreas secretes insulin, it also secretes glucagon, a hormone with the opposite effect: insulin captures sugar, while glucagon releases it. Diabetes is therefore due to an imbalance between these two hormones controlling the sugar level in the blood.”
Pancreatic cells, but also intestinal ones
estrogen administration to post-menopausal female mice led the Geneva scientists to make a first observation: they identified an increased tolerance to glucose, which is correlated to a lower risk of diabetes. However, if the effect on insulin was expected, the effect on glucagon — and especially on GLP1, an intestinal and pancreatic hormone that increases insulin production — was much less so. These results confirmed the sensitivity to estrogen of pancreatic alpha cells, which then secrete less hyperglycemic glucagon, but more GLP1. Also released by the intestine during the absorption of meal, this hormone stimulates the secretion of insulin, inhibits the secretion of glucagon and induces the feeling of satiety. The lack of GLP1 is therefore an essential piece — and so far little known — of the onset of diabetes. The role played by GLP1 represents a major explanation of the protection of women regarding diabetes onset before menopause.
“This first observation was already interesting,” explains Sandra Handgraaf. “But we went a step further: indeed, the gut harbours cells called the L cells that are very similar to pancreatic alpha cells and whose main function is precisely to produce GLP1. We also observed a strong increase in the production of GLP1 in the gut cells, thus proving the crucial role of the intestine in the control of carbohydrate balance and the influence of estrogens on the entire metabolisms at stake.” These results were also confirmed on human cells and tissue samples.
Interesting substitution treatments
Hormonal substitution treatments are often subject to negative publicity, mainly because of the cardiovascular risks associated with them. “It is important to remember that hormonal substitution, when taken at the beginning of menopause and for a few years only, does not cause any particular risk of cardiovascular events,” stresses Jacques Philippe. “However, if hormonal treatment is taken more than 10 years after menopause, the cardiovascular risk is effectively increased. In the context of diabetes, an estrogenic treatment allows to avoid, in all cases, the explosion of female diabetes cases. These treatments, well administered, can really add value for women’s health.”
Towards more targeted treatments
In their study, the Geneva researchers were also able to dissect the fine cellular mechanisms involved: Of the three estrogens receptors, only one is mainly involved in this protective effect. It would therefore be possible to develop a molecule that only activates the interesting receptor, with a much more targeted effect. “One could imagine a treatment that, without the side effects of a little too powerful hormonal therapy, would also address men,” concludes Sandra Handgraaf.
Source: Read Full Article